ProCE Banner Activity

ADRIATIC: Phase III Trial of Consolidation Therapy With Durvalumab for Limited-Stage Small-Cell Lung Cancer

Conference Coverage
Slideset

The first planned interim analysis of the ADRIATIC trial showed statistically significant and clinically relevant improvements in OS and PFS with durvalumab as consolidation treatment following concurrent chemoradiotherapy vs placebo in patients with limited-stage small-cell lung cancer.

Released: June 04, 2024

Expiration: June 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.